Life Sciences Research Partners V.Z.W.
VC Fund
Life Sciences Research Partners V.Z.W. is a VC fund focused on Medical and Health Care. Life Sciences Research Partners (formerly called D Collen Research Foundation) was founded by Emeritus Professor Désiré Collen in 1988.The purpose of Life Sciences Research Partners is, without any profit making intentions, to carry out, promote and support scientific research in general and biomedical and biotechnological research in particular.The specific activities by which the purposes of the association will be realized are among others the awarding of research grants, research mandates and traveling scholarships, the organization of scientific congresses and symposia, financial support of publications, and any other related activities that support or help to propagate the advancement of science.In addition, the association may conduct any other activity, that contributes directly or indirectly to its non-profit purpose, including commercial and profitable activities within legal boundaries, on condition that the profit thereof be exclusively spent on the non-profit purposes of the association.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Life Sciences Research Partners V.Z.W. invests in
Stages Life Sciences Research Partners V.Z.W. invests in
Countries Life Sciences Research Partners V.Z.W. invests in
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology,therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies). | $9.9M / Series A / May 03, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Life Sciences Research Partners V.Z.W. invest in?
Life Sciences Research Partners V.Z.W. invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Life Sciences Research Partners V.Z.W. last invest?
The most recent investment recorded for Life Sciences Research Partners V.Z.W. closed in May 2012. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!